Most Read Articles
Audrey Abella, 26 Jul 2017
Upstream use of the P2Y12 receptor antagonist ticagrelor provides benefit over clopidogrel in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) with a relatively rapid time to angiography, according to a post hoc analysis of the PLATO* trial.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

SSRI use not associated with cataract risk

30 Oct 2017

Use of selective serotonin reuptake inhibitors (SSRIs) does not appear to increase the risk of cataract, reports a recent study.

Researchers identified a total of 206,931 cataract cases matched with the same number of controls. There was no association between current long-term use of SSRI (≥20 prescriptions) and an increased cataract risk (adjusted odds ratio [aOR], 0.99; 95 percent CI, 0.94 to 1.03). On the other hand, a slightly increased risk of cataract was seen for long-term SSRI users compared with nonusers in a subgroup of patients aged 40 to 64 years.

“The slightly increased OR for individuals younger than 65 years of age in association with long-term SSRI use needs to be investigated in further studies,” researchers said.

In this case-control study, the authors derived the participants from the UK-based Clinical Practice Research Datalink (CPRD). Included were patients with first-time cataract aged ≥40 years between 1995 and 2015 and an equal number of cataract-free controls matched on age, sex, general practice, date of cataract recording (ie, index date) and years of history in the CPRD before the index date.

Conditional logistic regression analyses were conducted, adjusting for body mass index, smoking, hypertension, diabetes and systemic steroid use. The number of SSRI prescriptions and prescriptions for other antidepressant drugs were the exposure of interest. Mutually exclusive use of single SSRI substances was explored.

The index data was shifted backwards by 2 years in sensitivity analyses. Also, analyses were restricted to cases and controls without a prior glaucoma diagnosis.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 26 Jul 2017
Upstream use of the P2Y12 receptor antagonist ticagrelor provides benefit over clopidogrel in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) with a relatively rapid time to angiography, according to a post hoc analysis of the PLATO* trial.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.